Movement Alert｜GENSCRIPT B-1K Intraday Rise 3.21% in Regular Trading, CARVYKTI quarterly net trade sales reached about $710 million

Market Focus10-14

On October 14, GENSCRIPT B-1K rose 3.21% in regular trading, trading at HK$36.6, with turnover of HK$683 million.

The clearest catalyst was the company’s latest disclosure that associate Legend Biotech reported CARVYKTI net trade sales of about $710 million for the quarter ended September 30. The update points to continued commercial scale-up of the flagship CAR-T product and offers a direct fundamental data point for investors tracking the value of GENSCRIPT B-1K’s cell therapy exposure.

According to the company update, the sales figure was disclosed in a filing submitted by Legend Biotech to the US Securities and Exchange Commission under its collaboration and license agreement with Janssen. The company also noted that the number was based on information provided by Janssen, and neither Legend Biotech nor GENSCRIPT B-1K had independently verified the accuracy of that sales figure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment